GSI Clinical Research | Margate, FL

Research site

(Unclaimed)

Location

3275 N State Road 7, Margate, Florida, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Risankizumab

Lutikizumab

Dupilumab

RPT193

etrasimod

Sofpironium Bromide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 16 total trials

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (EMBARQ-CSU1)

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling

Chronic Spontaneous Urticaria

Biological: barzolvolimab

Biological: Matching placebo

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling

Atopic Dermatitis

Drug: Upadacitinib Dose B

Drug: Upadacitinib Dose A

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only

Vitiligo

Drug: Upadacitinib

Drug: Placebo

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (Intrepid)

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling

Hidradenitis Suppurativa

Drug: Lutikizumab

Drug: Placebo

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling

Hidradenitis Suppurativa

Drug: Placebo

Biological: Lutikizumab

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling

Alopecia Areata

Drug: Upadacitinib

Drug: Placebo

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1)

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting

Atopic Dermatitis

Drug: Upadacitinib

Drug: Placebo for Upadacitinib

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting

Atopic Dermatitis

Biological: Lebrikizumab

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (UnlIMMited)

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Active, not recruiting

Scalp Psoriasis

Genital Psoriasis

Drug: Risankizumab

Drug: Placebo for Risankizumab